GETI.B

202

+0.65%↑

CAMX

669

+0.22%↑

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

GETI.B

202

+0.65%↑

CAMX

669

+0.22%↑

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

GETI.B

202

+0.65%↑

CAMX

669

+0.22%↑

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

GETI.B

202

+0.65%↑

CAMX

669

+0.22%↑

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

GETI.B

202

+0.65%↑

CAMX

669

+0.22%↑

EKTA.B

47.08

-0.08%↓

VITR

129

+0.31%↑

AMBEA

132.4

+0.38%↑

Kodu・Aktsiate loetelu・BioArctic AB

B
BioArctic AB

Suletud

284.6 -2.47

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

284.2

Max

285.2

Põhinäitajad
By Trading Economics
Sissetulek	-896M 179M
Müük	-897M 392M
P/E Sektori keskmine	23.701 35.69
Aktsiakasum	1.09
Kasumimarginaal	45.668
Töötajad	119
EBITDA	-893M 188M

Turustatistika
By TradingEconomics
Turukapital	4.5B 25B
Eelmine avamishind	287.07
Eelmine sulgemishind	284.6

BioArctic AB Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. sept 2025, 18:25 UTC

Suurimad hinnamuutused turgudel

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

27. sept 2025, 07:00 UTC

Tulu

This Water Stock Is Dehydrated. What Could Bring It Back. -- Barrons.com

27. sept 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26. sept 2025, 21:56 UTC

Omandamised, ülevõtmised, äriostud

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26. sept 2025, 20:54 UTC

Tulu

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26. sept 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26. sept 2025, 20:27 UTC

Omandamised, ülevõtmised, äriostud

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26. sept 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26. sept 2025, 19:54 UTC

Market Talk

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26. sept 2025, 19:53 UTC

Omandamised, ülevõtmised, äriostud

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26. sept 2025, 19:40 UTC

Tulu

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26. sept 2025, 19:24 UTC

Market Talk

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26. sept 2025, 19:17 UTC

Market Talk

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26. sept 2025, 19:15 UTC

Market Talk

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26. sept 2025, 19:03 UTC

Market Talk

Global Equities Roundup: Market Talk

26. sept 2025, 19:03 UTC

Market Talk

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26. sept 2025, 18:50 UTC

Market Talk

Tulu

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26. sept 2025, 18:36 UTC

Market Talk

Silver Closes Out Week With Strong Surge -- Market Talk

26. sept 2025, 18:02 UTC

Omandamised, ülevõtmised, äriostud

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26. sept 2025, 18:02 UTC

Omandamised, ülevõtmised, äriostud

ING: Global Development Hasn't Received All Necessary Approvals >ING

26. sept 2025, 18:02 UTC

Omandamised, ülevõtmised, äriostud

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26. sept 2025, 17:54 UTC

Market Talk

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26. sept 2025, 16:56 UTC

Market Talk

Tulu

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26. sept 2025, 16:41 UTC

Market Talk

Tulu

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26. sept 2025, 16:26 UTC

Tulu

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26. sept 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

26. sept 2025, 16:12 UTC

Market Talk

Nike Stock Seen With Limited Upside -- Market Talk

26. sept 2025, 15:59 UTC

Market Talk

Global Equities Roundup: Market Talk

26. sept 2025, 15:59 UTC

Market Talk

Nike Seen Showing Progress in Turnaround -- Market Talk

Võrdlus sarnastega

Hinnamuutus

BioArctic AB Prognoos

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest BioArctic AB

BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.